FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека стаков

Post-Viral Recovery

Immune Supportintermediate

83

синергия

83
Share
Пептиды

3

Среднедневная дозировка мкг

2,100

Уровень

intermediate

Добавлено

May 17, 2026

Обзор

The Post-Viral Recovery stack is designed for individuals experiencing persistent fatigue, immune dysregulation, and inflammatory symptoms following viral infections — including but not limited to long COVID, post-EBV syndromes, and chronic fatigue syndrome with viral triggers. The protocol increases Thymosin Alpha-1 frequency to 3x weekly (from the standard 2x) to provide more aggressive immune reconstitution. Ta1''s ability to restore T-cell subset ratios (CD4/CD8 balance), enhance dendritic cell maturation, and promote interferon production makes it the cornerstone of post-viral immune recovery. Clinical data from COVID-19 treatment showed Ta1 reduced mortality and improved T-cell counts in critically ill patients. LL-37 is the only human cathelicidin — an antimicrobial peptide produced by neutrophils, macrophages, and epithelial cells as a first-line defense against pathogens. Beyond direct antimicrobial activity (it disrupts bacterial and viral membranes), LL-37 modulates immune cell recruitment, promotes wound healing, and importantly, helps resolve chronic inflammation by promoting macrophage phenotype switching from M1 (pro-inflammatory) to M2 (resolving/repair). In post-viral syndromes, persistent M1-dominant inflammation drives ongoing symptoms; LL-37 may help break this cycle. BPC-157 at twice-daily dosing provides systemic anti-inflammatory support and gut healing — critical because many post-viral syndromes involve gut barrier disruption and microbial translocation that perpetuate immune activation. Its modulation of the nitric oxide system and multiple growth factor pathways creates a tissue-repair environment throughout the body. The three-peptide combination addresses post-viral recovery comprehensively: Ta1 restores immune competence, LL-37 resolves chronic inflammation and provides antimicrobial coverage, and BPC-157 repairs tissue damage and restores gut barrier function. This is classified as intermediate due to the three-compound regimen and the clinical complexity of post-viral conditions.

Протокол дозирования

Thymosin Alpha-1

3x/week· subcutaneous

Читать больше о Thymosin Alpha-1 →

1,500 mcg

на дозу

LL-37

Every day· subcutaneous

Читать больше о LL-37 →

100 mcg

на дозу

BPC-157

Twice per day· subcutaneous

Читать больше о BPC-157 →

250 mcg

на дозу

Цели и доказательства

Post-viral fatigueImmune reconstitutionInflammationLong COVIDRecovery
Уровень доказательств:Данные от человека

Предупреждения

  • LL-37 is an antimicrobial peptide with emerging research for post-viral syndromes. Limited human data outside of wound healing. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad as Zadaxin).

Comments

Sign in to join the discussion

Уведомление: Этот стак представлен сообществом и предназначен для исследовательских целей только. Peptide Contacts не проверяет безопасность или эффективность представленных стаков. Всегда проконсультируйтесь с квалифицированным медицинским специалистом перед использованием любого протокола пептидов.